📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Kilitch Drugs Approves 1:1 Bonus Issue and Increase in Authorized Capital at EGM
Kilitch Drugs (India) Limited successfully conducted its Extraordinary General Meeting (EGM) on March 13, 2026. Shareholders approved the issuance of bonus shares in a 1:1 ratio, meaning investors will receive one additional share for every share held. The meeting also authorized an increase in the company's share capital and necessary amendments to the Memorandum of Association. The record date for the bonus allotment will be determined and announced by the Board in due course.
Key Highlights
Approval of 1:1 Bonus Issue for all eligible shareholders as of the upcoming record date
Resolution passed to increase the Authorized Capital of the company and amend the Memorandum of Association
EGM held on March 13, 2026, with participation from 3 promoter group members and 45 public shareholders
The meeting was conducted via video conferencing and concluded within 12 minutes with all resolutions transacted
💼 Action for Investors
Existing shareholders should monitor for the announcement of the record date to ensure eligibility for the 1:1 bonus shares. Note that while share count will double, the stock price will adjust proportionally on the ex-bonus date.
Kilitch Drugs Approves 1:1 Bonus Issue and Capital Increase at EGM
Kilitch Drugs (India) Limited successfully conducted an Extraordinary General Meeting on March 13, 2026. The shareholders approved a 1:1 bonus share issue, which will double the total number of equity shares. Additionally, the company received approval to increase its authorized share capital to support the bonus issuance. The Board of Directors will determine the record date for the allotment in due course.
Key Highlights
Approved 1:1 bonus share issuance to existing shareholders as of the upcoming record date.
Authorized the increase of the company's share capital and subsequent amendment of the Memorandum of Association.
The EGM was held via video conferencing with participation from 48 members (3 promoters and 45 public).
The meeting was brief, commencing at 11:30 am and concluding at 11:42 am on March 13, 2026.
💼 Action for Investors
Investors should track the upcoming announcement regarding the record date to qualify for the 1:1 bonus. Note that the stock price will adjust proportionally on the ex-bonus date to reflect the increased share count.
Kilitch Drugs Announces 1:1 Bonus Issue and Increase in Authorized Capital
Kilitch Drugs (India) Limited has scheduled an Extraordinary General Meeting (EGM) on March 13, 2026, to seek shareholder approval for a 1:1 bonus share issuance. The company plans to capitalize up to INR 17.48 crore from its Free Reserves or Securities Premium to issue approximately 1.75 crore new equity shares. To facilitate this, the authorized share capital will be increased from INR 25 crore to INR 40 crore. Shareholders on record as of March 4, 2026, will be eligible for e-voting on these proposals.
Key Highlights
Proposed 1:1 bonus issue, providing one new equity share for every one existing share held
Increase in Authorized Share Capital from INR 25,00,00,000 to INR 40,00,00,000
Capitalization of a sum not exceeding INR 17,48,07,820 from reserves for the bonus issue
EGM to be held on March 13, 2026, with remote e-voting from March 9 to March 12, 2026
Cut-off date for determining e-voting eligibility is March 4, 2026
💼 Action for Investors
Investors should monitor the official announcement of the Record Date following the EGM approval to ensure eligibility for the bonus shares. While the number of shares will double, the stock price will adjust proportionally, improving liquidity for retail participants.
Kilitch Drugs Announces 1:1 Bonus Issue and Q3 FY26 Results; Revenue Jumps 170% YoY
Kilitch Drugs (India) Limited has recommended a 1:1 bonus issue, providing one free equity share for every share held, subject to shareholder approval. For Q3 FY26, the company reported a massive 170% year-on-year surge in standalone revenue to ₹44.67 crore, although net profit declined to ₹4.89 crore from ₹6.88 crore in the same period last year. The company is also increasing its authorized share capital to ₹40 crore to facilitate the bonus issuance. These developments follow a recent ₹49.92 crore rights issue aimed at funding a Greenfield Project at Pen, signaling aggressive expansion.
Key Highlights
Approved 1:1 Bonus Issue by capitalizing free reserves and securities premium of ₹17.48 crore.
Standalone Q3 FY26 revenue from operations rose to ₹44.67 crore versus ₹16.51 crore in Q3 FY25.
Net profit for the quarter stood at ₹4.89 crore, impacted by higher material costs and export commissions.
Authorized share capital increased from ₹25 crore to ₹40 crore to accommodate the new equity base.
Recently completed a ₹49.92 crore rights issue in August 2025 for capital expenditure on a Greenfield Project.
💼 Action for Investors
The 1:1 bonus issue is a positive signal for retail liquidity, though investors should monitor the compression in net profit margins despite the high revenue growth. The progress of the Greenfield Project at Pen will be the primary driver for long-term value creation.
Kilitch Drugs Announces 1:1 Bonus Issue and Reports Q3 FY26 Results
Kilitch Drugs (India) Limited has approved a 1:1 bonus issue, meaning shareholders will receive one additional share for every one share held. The company reported standalone net sales of ₹44.67 crore for Q3 FY26, a significant jump from ₹16.51 crore in the same quarter last year. However, net profit for the quarter declined to ₹4.89 crore from ₹6.88 crore YoY, primarily due to a high base of 'Other Income' in the previous year. The board also approved increasing the authorized share capital from ₹25 crore to ₹40 crore to facilitate this corporate action.
Key Highlights
Approved 1:1 bonus issue of equity shares of face value ₹10 each
Standalone Net Sales grew to ₹44.67 crore in Q3 FY26 from ₹16.51 crore in Q3 FY25
Net Profit after tax stood at ₹4.89 crore for the quarter ended December 31, 2025
Authorized share capital increased to ₹40 crore from ₹25 crore subject to member approval
Estimated completion date for bonus share credit is April 10, 2026
💼 Action for Investors
The 1:1 bonus issue will increase liquidity and make the stock more affordable for retail investors, though it does not change the company's fundamental value. Investors should monitor the strong growth in core operational revenue while keeping an eye on the volatility of non-operating income.
Kilitch Drugs Announces 1:1 Bonus Issue; Q3 Revenue Surges to ₹44.67 Crore
Kilitch Drugs (India) Limited has approved a 1:1 bonus issue, meaning shareholders will receive one additional share for every share held as of the record date. The company reported a significant jump in standalone revenue for Q3 FY26 to ₹4,467 lakhs, up from ₹1,651 lakhs in the same quarter last year. However, standalone net profit for the quarter declined to ₹489 lakhs from ₹688 lakhs YoY due to increased operational expenses. The board has also proposed increasing the authorized share capital from ₹25 crore to ₹40 crore to facilitate the bonus issuance.
Key Highlights
Approved 1:1 bonus issue by capitalizing ₹17.48 crore from free reserves and securities premium.
Standalone Q3 FY26 revenue grew 170% YoY to ₹4,467 lakhs from ₹1,651 lakhs.
Standalone Net Profit for Q3 FY26 stood at ₹489.08 lakhs compared to ₹688.30 lakhs YoY.
Authorized share capital increased to ₹40 crore from ₹25 crore, subject to shareholder approval.
Bonus shares are expected to be credited or dispatched by April 10, 2026.
💼 Action for Investors
Investors should maintain a positive outlook due to the bonus issue which will enhance liquidity, though the dip in net profit despite high revenue growth warrants a closer look at margin pressures. Monitor the EGM on March 13, 2026, for final approval and the subsequent announcement of the record date.